CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,061 enrolled
Drug / intervention
NUCALA Injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03028480
NCT03028480N/ACompleted
CompareCT.gov

Nucala® Subcutaneous Injection Special Drug Use Investigation (Long-Term)

GlaxoSmithKline·observational·Posted Jan 23, 2017·Updated Sep 20, 2024

In Brief

An observational study evaluating NUCALA Injection for Asthma. Completed, enrolled 1,061 participants.

Detailed Summary

This study is a special drug use investigation program of NUCALA (a brand name for Mepolizumab) administered subcutaneously (SC). In this study the information regarding the safety and effectiveness of long term use of NUCALA after subcutaneous injection will be collected from Asthma subjects in daily clinical practice. The observation period per subject will be 52 weeks from the initiation of NUCALA treatment with follow-up investigation for 2 years after the observation period. NUCALA is a registered trademark of the GlaxoSmithKline \[GSK\] group of companies

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJan 23, 2017
Enrollment StartJan 11, 2017
Primary CompletionNov 22, 2023
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 9.4 years ago

Interventions

NUCALA Injectiondrug

Single dose of NUCALA SC will be administered. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.